Studi Penggunaan Obat pada Pasien Penyakit Paru Obstruktif Kronik di RSUD R.T. Notopuro Sidoarjo
Artikel Sidebar
-
Drug-Related Problems, PPOK, Interaksi obat, Penggunaan obat
Abstrak
Penyakit Paru Obstruktif Kronik (PPOK) merupakan salah satu penyebab utama morbiditas dan mortalitas global, dengan prevalensi yang terus meningkat terutama pada populasi lansia dan perokok. Penatalaksanaan PPOK memerlukan terapi jangka panjang dengan regimen obat yang kompleks, seperti bronkodilator, antiinflamasi, mukolitik dan antibiotik, sehingga meningkatkan risiko terjadinya masalah terkait obat (Drug-Related Problems/DRPs). Penelitian ini bertujuan untuk mengkaji pola farmakoterapi pada pasien PPOK rawat inap di RSUD R.T. Notopuro Sidoarjo. Penelitian ini menggunakan desain observasional deskriptif dengan pendekatan retrospektif, melalui telaah rekam medis 84 pasien yang dirawat pada periode Januari-Desember 2024. Data yang dikumpulkan mencakup karakteristik demografi pasien, jenis dan pola penggunaan obat, dosis, rute pemberian, frekuensi, lama terapi, serta potensi DRPs. Hasil penelitian menunjukkan golongan bronkodilator yang paling banyak digunakan, yakni salbutamol (10,02%), dan kombinasi salbutamol+ipratropium (13,60%), golongan antiinflamasi paling banyak diberikan metilprednisolon (12,41%), golongan mukolitik paling banyak diberikan N-asetilsistein (9,79%), dan golongan antibiotik paling banyak diberikan levofloksasin (6,44%). Regimen dosis dan lama pemberian diberikan berdasarkan kondisi klinis pasien. Terdapat 32 pasien menerima pergantian antibiotik selama perawatan. DRPs paling dominan berupa interaksi dengan tingkat keparahan moderate pada metilprednisolon-aminofilin (32,7%) dan mayor pada levofloksasin-metilprednisolon (34,7%). Hasil ini menegaskan pentingnya pemantauan terapi untuk mencegah DRPs dan mengoptimalkan hasil klinis pada pasien PPOK.
Artikel teks lengkap
Referensi
Agrawal, R., Moghtader, S., Ayyala, U., Bandi, V., & Sharafkhaneh, A. (2019). Update on management of stable chronic obstructive pulmonary disease. Journal of Thoracic Disease, 11(Suppl 14), S1800–S1809.
Aliyah, M. (2020). Pola penggunaan obat bronkodilator pada pasien penyakit paru obstruktif kronis di Rumah Sakit Umum Daerah Kabupaten Sidoarjo [Undergraduate thesis, Universitas Katolik Widya Mandala Surabaya].
Allfazmy, P. W., Warlem, N., & Amran, R. (2022). Faktor risiko penyakit paru obstruksi kronik (PPOK) di Semen Padang Hospital (SPH). Scientific Journal, 1(1), 19–23.
Amier, R. P., Hasrul, dan Wasliaty. (2021). Gambaran penggunaan obat pada pasien rawat inap pengidap penyakit paru obstruksi kronik (PPOK) di Rumah Sakit Nene Mallomo [Laporan penelitian]. ITKES Muhammadiyah Sidrap.
Ashraf, M. N., Khan, M. A., Imran, M., Fazal, I., Hassan, Z., & Alam, L. (2023). Comparison of efficacy of nebulized salbutamol with salbutamol/ipratropium combination in acute exacerbation of chronic obstructive pulmonary disease. Pakistan Armed Forces Medical Journal, 73(1), 36–39.
Badan Pusat Statistik Indonesia. (2024). Persentase penduduk berumur 15 tahun ke atas yang merokok tembakau selama sebulan terakhir menurut provinsi, 2024. Diakses 12 Desember 2024, dari https://www.bps.go.id/id/statistics-table/2/MTQzNSMy/persentase-penduduk-berumur-15-tahun-ke-atas-yang-merokok-tembakau-selama-sebulan-terakhir-menurut-provinsi.html
Barbagelata, E., Nicolini, A., Immacolata, A., & Politi, C. (2018). Gender differences and chronic obstructive pulmonary disease: An update on the literature. Italian Journal of Medicine, 12, 171–179.
Bilgis, A. A. (2024). Kelurahan Sehat Paru melalui program YOGA PPOK di Kelurahan Siwalankerto Surabaya. Jurnal Kesehatan Masyarakat Indonesia, 1(4), 93–96.
Devulder, J. V. (2024). Unveiling mechanisms of lung aging in COPD: A promising target for therapeutics development. Chinese Medical Journal Pulmonary and Critical Care Medicine, 2(3), 133–141.
Ding, Z., Li, X., Lu, Y., Rong, G., Yang, R., Zhang, R., Wang, G., Wei, X., Ye, Y., Qian, Z., Liu, H., Zhu, D., Zhou, R., Zhu, K., Ni, R., Xia, K., Luo, N., & Pei, C. (2016). A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Respiratory Medicine, 121, 39–47.
Drugs.com. (2025). Drug interactions checker. Diakses 6 Januari 2025, dari https://www.drugs.com/drug_interactions.html
Farida, Y., Putri, V. W., Hanafi, M., & Herdianti, N. S. (2020). Profil pasien dan penggunaan antibiotik pada kasus community-acquired pneumonia rawat inap di Rumah Sakit Akademik wilayah Sukoharjo. Journal of Pharmaceutical Science and Clinical Research, 5(2), 151–164.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). (2023). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2023 report. Global Initiative for Chronic Obstructive Lung Disease.
Gupta, V., Yu, K. C., Schranz, J., & Gelone, S. P. (2020). A multicenter evaluation of the US prevalence and regional variation in macrolide-resistant S. pneumoniae in ambulatory and hospitalized adult patients in the United States. Open Forum Infectious Diseases, 8(3).
Hidayat, F., Setiadi, A. P., & Setiawan, E. (2017). Analisis penggunaan dan biaya antibiotik di ruang rawat intensif sebuah rumah sakit di Surabaya. Pharmaciana, 7(2), 213–230.
Kim, S. H., Lee, H., Kim, Y., Rhee, C. K., Min, K. H., Hwang, Y. I., Kim, D. K., Park, Y. B., Yoo, K. H., & Moon, J. Y. (2023). Recent prevalence of and factors associated with chronic obstructive pulmonary disease in a rapidly aging society: Korea National Health and Nutrition Examination Survey 2015–2019. Journal of Korean Medical Science, 38(14), 108.
Kiser, T. H., Sevransky, J. E., Krishnan, J. A., Tonascia, J., Wise, R. A., Checkley, W., Walsh, J. W., Sullivan, J. B., Wilson, K. C., Moss, M., & Vandivier, R. W. (2017). A survey of corticosteroid dosing for exacerbations of chronic obstructive pulmonary disease requiring assisted ventilation. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, 4(3), 186–193.
Kopsaftis, Z. A., Sulaiman, N. S., Mountain, O. D., Carson-Chahhoud, K. V., Phillips, P. A., & Smith, B. J. (2018). Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: Systematic review. Systematic Reviews, 7(1), 213.
Li, Q., Qu, H. J., Lv, D., Yeh, M. K., Sun, S., Li, L., & Liao, Y. (2019). Drug-related problems among hospitalized patients with COPD in mainland China. International Journal of Clinical Pharmacy, 41, 1507–1515.
Ma, L. H., Jia, L., & Bai, L. (2023). Safety outcomes of salbutamol: A systematic review and meta-analysis. Clinical Respiratory Journal, 17(12), 1254–1264.
Medscape. (2025). Medscape Drugs dan Diseases [Computer software]. WebMD, LLC. Diakses 26 Juni 2025, dari https://www.medscape.com/public/medscapeapp
Messous, S., Trabelsi, I., Bel Haj Ali, K., Abdelghani, A., Ben Daya, Y., Razgallah, R., Grissa, M. H., Beltaief, K., Mezgar, Z., Belguith, A., Bouida, W., Boukef, R., Boubaker, H., Msolli, M. A., Sekma, A., & Nouira, S. (2022). Two-day versus seven-day course of levofloxacin in acute COPD exacerbation: A randomized controlled trial. Therapeutic Advances in Respiratory Disease, 16, 1–10.
Milne, K. M., Mitchell, R. A., Ferguson, O. N., Hind, A. S., & Guenette, J. A. (2024). Sex differences in COPD: From biological mechanisms to therapeutic considerations. Frontiers in Medicine, 11, 1289259.
Minov, J., Stoleski, S., Petrova, T., Vasilevska, K., Mijakoski, D., & Karadzinska-Bislimovska, J. (2020). Efficacy and safety of levofloxacin in the outpatient treatment of exacerbation of chronic obstructive pulmonary disease: Levofloxacin 750 mg vs. levofloxacin 500 mg. Health and Primary Care, 4, 1–5.
Miyazaki, T., Fukushima, K., Hashiguchi, K., Inoue, Y., Mihara, T., Sawai, T., Suyama, N., Kobayashi, T., Kondo, A., Fukuda, Y., Harada, Y., Sasaki, E., Kaku, N., Ide, S., Takazono, T., Saijo, T., Kosai, K., Morinaga, Y., Nakamura, S., Yamamoto, K., … Mukae, H. (2019). Efficacy and safety of cefditoren pivoxil for exacerbations of chronic obstructive pulmonary disease: A prospective multicenter interventional study. Journal of Infection and Chemotherapy, 25(9), 702–707.
Nego, M. A., & Gayatri, A. (2023). Potensi interaksi obat tersering pada pasien sakit kritis. Journal of the Indonesian Medical Association, 73(4), 206–212.
National Institute for Health and Care Excellence. (2018). Chronic obstructive pulmonary disease (acute exacerbation): Antimicrobial prescribing (NICE Guideline NG114). https://www.nice.org.uk/guidance/ng114
Papadopoulou, E., Hansel, J., Lazar, Z., Kostikas, K., Tryfon, S., Vestbo, J., & Mathioudakis, A. G. (2023). Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: A meta-analysis. European Respiratory Review, 32(167), 220141. https://doi.org/10.1183/16000617.0141-2022
Perhimpunan Dokter Paru Indonesia. (2023). Penyakit paru obstruktif kronik: Pedoman diagnosis dan penatalaksanaan di Indonesia (B. Antariksa, A. Bahtiar, & W. H. Wiyono, Ed.). Perhimpunan Dokter Paru Indonesia.
Poole, P., Chong, J., & Cates, C. J. (2019). Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, 2019(5), CD001287.
Rachmawan, F. E., & Hajma, L. P. A. (2024). Evaluasi antibiotik pada pasien rawat inap eksaserbasi akut penyakit paru obstruktif kronik (PPOK). Usadha: Journal of Pharmacy, 3(2), 227–241.
Rodrigues, S. O., Cunha, C. M. C. D., Soares, G. M. V., Silva, P. L., Silva, A. R., & Gonçalves-de-Albuquerque, C. F. (2021). Mechanisms, pathophysiology and currently proposed treatments of chronic obstructive pulmonary disease. Pharmaceuticals, 14(10), 979.
Rogliani, P., Manzetti, G. M., Gholamalishahi, S., Cazzola, M., & Calzetta, L. (2024). Impact of N-acetylcysteine on mucus hypersecretion in the airways: A systematic review. International Journal of Chronic Obstructive Pulmonary Disease, 19, 2347–2360.
Rosenwasser, Y., Berger, I., & Loewy, Z. G. (2022). Therapeutic approaches for chronic obstructive pulmonary disease (COPD) exacerbations. Pathogens, 11(12), 1513.
Samirah, S., Aryani, T., Puspitasari, A. D., Ibrahim, M. A., Lutfiyah, B. I., & Rasyid, A. N. (2023). Therapy pattern of bronchodilators in chronic obstructive pulmonary disease (COPD) patients with acute exacerbations. Pharmacy Education, 23(4), 224–227.
Sankar, V., Durga, K., Priya, K., Jose, S., Joseph, R. M., & Thomas, P. M. (2016). Open label observational comparative efficacy study
of ceftriaxone and levofloxacin in COPD exacerbations. Journal of Pharmacy Practice and Community Medicine, 2(2), 46–53.
Sari, C. P., Hanifah, S., Rosdiana, & Anisa, Y. (2021). Efektivitas pengobatan pada pasien penyakit paru obstruktif kronis (PPOK) di rumah sakit wilayah Yogyakarta. Jurnal Manajemen dan Pelayanan Farmasi, 11(4), 215–227.
Wedzicha, J. A., Miravitlles, M., Hurst, J. R., Calverley, P. M. A., Albert, R. K., Anzueto, A., Criner, G. J., Dransfield, M. T., Frois, F., Gould, G. A., MacNee, W., Make, B., Martínez, F. J., Nici, L., Papi, A., Rabe, K. F., Rennard, S. I., Roche, N., Sethi, S., … Woodhead, M. (2017). Management of COPD exacerbations: A European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal, 49(3), 1600791.
Williams, D. M., & Bourdet, S. V. (2015). Chronic obstructive pulmonary disease. In T. L. Schwinghammer et al. (Eds.), Pharmacotherapy handbook: A pathophysiologic approach (9th ed., pp. 835–843). McGraw-Hill.
World Health Organization. (2024). Chronic obstructive pulmonary disease (COPD). Diakses 3 Desember 2024, dari https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
Wu, P., Jiang, Y. Q., Si, F. L., Wang, H. Y., Song, X. B., Sheng, C. F., Xu, X., Li, F., & Zhang, J. (2024). Pharmaceutical treatment status of patients with COPD in the community based on a medical Internet of Things: A real-world study. NPJ Primary Care Respiratory Medicine, 34(1), 10.
Zulkarni, R., Nessa, N., & Athifah, Y. (2019). Analisis ketepatan pemilihan dan penentuan regimen obat pada pasien penyakit paru obstruktif kronis (PPOK). Jurnal Sains Farmasi dan Klinis, 6(2), 158–163.
Penulis
Hak Cipta (c) 2026 Firnanda Berliana, Hanif Rifqi Praseytawan, Novamei Indriani, Dewi Perwito Sari
Artikel ini berlisensiCreative Commons Attribution-ShareAlike 4.0 International License.
Penulis tetap memegang hak atas karyanya dan memberikan hak publikasi pertama kepada jurnal ini yang secara simultan karya tersebut dilisensikan di bawah: Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0)